Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Change in Receivables: 2021-2025

Historic Change in Receivables for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -$62,000.

  • Silence Therapeutics' Change in Receivables rose 96.46% to -$62,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year decrease of 119.77%. This contributed to the annual value of $904,000 for FY2024, which is 330.61% up from last year.
  • Silence Therapeutics' Change in Receivables amounted to -$62,000 in Q3 2025, which was down 875.00% from $8,000 recorded in Q2 2025.
  • Silence Therapeutics' Change in Receivables' 5-year high stood at $10.0 million during Q1 2024, with a 5-year trough of -$8.0 million in Q2 2024.
  • For the 3-year period, Silence Therapeutics' Change in Receivables averaged around $30,150, with its median value being $8,000 (2025).
  • Over the last 5 years, Silence Therapeutics' Change in Receivables had its largest YoY gain of 1,158.72% in 2024, and its largest YoY loss of 1,082.76% in 2024.
  • Over the past 5 years, Silence Therapeutics' Change in Receivables (MRQ) stood at -$2.5 million in 2021, then surged by 62.53% to -$920,749 in 2022, then surged by 131.54% to $290,430 in 2023, then surged by 110.38% to $611,000 in 2024, then plummeted by 110.15% to -$62,000 in 2025.
  • Its Change in Receivables was -$62,000 in Q3 2025, compared to $8,000 in Q2 2025 and -$940,000 in Q1 2025.